Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

What is the purpose of this trial?

This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome.


Participation Guidelines

Ages: 6 - 18 years

Gender: Both


Neurocrine Biosciences, Inc.

Start Date: 11/29/2018

End Date: 06/30/2019

Last Updated: 12/10/2018

Study HIC#: 2000022997

Get Involved

For more information about this study, contact:
David Zakur
+1 203-785-6906
david.zakur@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Michael Bloch

Principal Investigator

Sub-Investigators